Your solution


CAS: 179324-69-7

In 2003, Bortezomib became the first proteasome inhibitor approved by the U.S. FDA.
Bortezomib is a pyrazine and boronic acid derivative used as an antineoplastic agent in the treatment of multiple myeloma and mantle cell lymphoma.
It may be used in combination with dexamethasone or prednisone, among others.
Bortezomib is on the World Health Organization model list of essential medicines.

Therapeutic group
Antineoplastic agents, proteasome inhibitors
ATC code: L01XG01
Your selection

How can we support you with Bortezomib?

I am looking for..